Development of Drugs & Drug Testing
Computational modelling is used to predict how a drug might interact with biological systems based on chemical structure and known physiological targets. These predictions help prioritise which compounds should proceed to physical testing and reduce unnecessary laboratory experimentation.
Laboratory tissue testing exposes isolated human or animal cells to the drug to observe its direct biological effects. This approach allows researchers to identify toxicity, dosage thresholds, and mechanisms without risking harm to whole organisms.
Animal testing evaluates a drug’s systemic impact, including metabolism, organ function, and potential long‑term effects. Animals provide whole‑body responses unavailable from tissue tests, helping determine whether human trials are ethically permissible.
Clinical trial phases systematically scale testing from small groups of healthy volunteers to large populations of patients. Each phase is designed to collect specific types of data, such as safety, dosage, efficacy, and comparison to existing treatments.
| Concept | Early Testing | Late Clinical Phases |
|---|---|---|
| Primary Goal | Assess safety and dosage | Evaluate effectiveness and compare treatments |
| Participants | Healthy volunteers or lab systems | Large numbers of patients |
| Risk Tolerance | Low | Moderate with medical supervision |
Identify the purpose of each clinical phase, as exam questions often test understanding of the logical progression from safety to effectiveness. Always link each phase to its unique experimental focus and participant type.
Explain why placebos are used, focusing on controlling psychological factors rather than simply substituting an inactive substance. Examiners look for justification based on bias reduction and fair comparison.
Emphasise the role of double‑blind design when interpreting trial reliability. Make sure to articulate how it protects against researcher influence and enhances data objectivity.
Use precise terminology such as ‘side effects’, ‘effectiveness’, and ‘dosage determination’ to demonstrate conceptual clarity. Avoid vague generalisations about trials or drug behaviour.
Clearly distinguish preclinical from clinical testing, noting that human testing cannot begin until preclinical data confirm acceptable safety.
Assuming all testing begins with human participants can lead to incorrect answers. Stress that computational, tissue, and animal studies must indicate safety before exposing humans to the drug.
Confusing placebos with low‑dose versions of drugs misrepresents their function. A placebo contains no active ingredient and is intended solely to isolate psychological effects.
Believing double‑blind studies are optional undermines understanding of bias control. They are essential whenever subjective evaluation could influence results.
Misrepresenting the goals of each clinical phase, such as thinking phase 1 tests effectiveness, is a frequent error. Phase 1’s purpose is exclusively safety, tolerance, and dosage estimation.
Pharmacology connects drug testing principles to mechanisms of action at the molecular level. Understanding how a drug interacts with receptors or enzymes can predict its behaviour during testing.
Epidemiology contributes statistical tools used to evaluate data from large phase 3 trials. Concepts such as randomisation, sample size, and confidence intervals determine the reliability of results.
Bioethics provides the framework for informed consent, humane animal treatment, and risk justification. These considerations guide both regulatory requirements and experimental design choices.
Biotechnology supports drug development through techniques such as genetic engineering and high‑throughput screening. These technologies accelerate preclinical discovery and optimise drug candidates.